Cargando…
RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1)
Glioblastoma multiform (GBM) is the most frequent type of malignant brain tumor with a poor prognosis. After optimal surgery, radiotherapy plus temozolomide (TMZ) is the standard treatment for GBM patients. However, the development of TMZ resistance limits its efficacy in GBM management. Runt Relate...
Autores principales: | Xu, Jianglong, Song, Jia, Xiao, Menglin, Wang, Changsheng, Zhang, Qisong, Yuan, Xiaoye, Tian, Shaohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810036/ https://www.ncbi.nlm.nih.gov/pubmed/34895074 http://dx.doi.org/10.1080/21655979.2021.2009976 |
Ejemplares similares
-
Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme
por: Tivnan, Amanda, et al.
Publicado: (2015) -
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation
por: de Souza, I., et al.
Publicado: (2022) -
RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner
por: Abdallah, Mohamed Gaber, et al.
Publicado: (2021) -
RNA Sequencing Reveals Upregulation of RUNX1-RUNX1T1 Gene Signatures in Clear Cell Renal Cell Carcinoma
por: Xiong, Zuquan, et al.
Publicado: (2014) -
The RUNX1/RUNX1T1 network: translating insights into therapeutic options
por: Swart, Laura E., et al.
Publicado: (2021)